Impact of a Combined Continuous Glucose Monitoring-Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes: Real-World, Observational Study

被引:2
作者
Kumbara, Abhimanyu B. [1 ]
Iyer, Anand K. [1 ]
Green, Courtney R. [2 ]
Jepson, Lauren H. [2 ]
Leone, Keri [2 ]
Layne, Jennifer E. [2 ]
Shomali, Mansur [1 ]
机构
[1] Welldoc Inc, Suite 150,10221 Wincopin Cir, Columbia, MD 21044 USA
[2] Dexcom Inc, San Diego, CA USA
来源
JMIR DIABETES | 2023年 / 8卷
关键词
type2; diabetes; digital health; continuous glucose monitoring; artificial intelligence; glycemic outcomes; engagement; digital health intervention; mHealth; diabetes management;
D O I
10.2196/47638
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The BlueStar (Welldoc) digital health solution for people with diabetes incorporates data from multiple devices and generates coaching messages using artificial intelligence. The BlueStar app syncs glucose data from the G6 (Dexcom) real-time continuous glucose monitoring (RT-CGM) system, which provides a glucose measurement every 5 minutes. Objective: The objective of this real-world study of people with type 2 diabetes (T2D) using the digital health solution and RT-CGM was to evaluate change in glycemic control and engagement with the program over 3 months. Methods: Participants were current or former enrollees in an employer-sponsored health plan, were aged 18 years or older, had a T2D diagnosis, and were not using prandial insulin. Outcomes included CGM-based glycemic metrics and engagement with the BlueStar app, including logging medications taken, exercise, food details, blood pressure, weight, and hours of sleep. Results: Participants in the program that met our analysis criteria (n=52) were aged a mean of 53 (SD 9) years; 37% (19/52) were female and approximately 50% (25/52) were taking diabetes medications. The RT-CGM system was worn 90% (SD 8%) of the time over 3 months. Among individuals with suboptimal glycemic control at baseline, defined as mean glucose >180 mg/dL, clinically meaningful improvements in glycemic control were observed, including reductions in a glucose management indicator (-0.8 percentage points), time above range 181-250 mg/dL (-4.4 percentage points) and time above range >250 mg/dL (-14 percentage points; all P<.05). Time in range 70-180 mg/dL also increased by 15 percentage points (P=.016) in this population, which corresponds to an increase of approximately 3.5 hours per day in the target range. Over the 3-month study, 29% (15/52) of participants completed at least one engagement activity per week. Medication logging was completed most often by participants (23/52, 44%) at a rate of 12.1 (SD 0.8) events/week, and this was closely followed by exercise and food logging. Conclusions: The combination of an artificial intelligence-powered digital health solution and RT-CGM helped people with T2D improve their glycemic outcomes and diabetes self-management behaviors.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Exploring the Impact of Dawn Phenomenon on Glucose-Guided Eating Thresholds in Individuals With Type 2 Diabetes Using Continuous Glucose Monitoring: Observational Study
    Jospe, Michelle R.
    Marano, Kari M.
    Bedoya, Arianna R.
    Behrens, Nick L.
    Cigan, Lacey
    Villegas, Vanessa
    Magee, Michelle F.
    Marrero, David G.
    Richardson, Kelli M.
    Liao, Yue
    Schembre, Susan M.
    JMIR FORMATIVE RESEARCH, 2023, 7
  • [22] Impact of Real-Time Continuous Glucose Monitoring Data Sharing on Quality of Life and Health Outcomes in Adults with Type 1 Diabetes
    Polonsky, William H.
    Fortmann, Addie L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (03) : 195 - 202
  • [23] Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
    Gavin, James R., III
    Bailey, Clifford J.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : S19 - S27
  • [24] Can digital health apps provide patients with support to promote structured diabetes education and ongoing self-management? A real-world evaluation of myDiabetes usage
    Blythin, A. M.
    Elkes, J.
    van Lindholm, T.
    Bhogal, A.
    Wilkinson, T. M. A.
    Saville, C.
    Kirk, A.
    DIGITAL HEALTH, 2023, 9
  • [25] REAL-WORLD OBSERVATIONAL STUDY REGARDING GLUCOSE CONTROL IN INSULIN TREATED DIABETES MELLITUS PATIENTS. GLUCOSE VARIABILITY PATTERNS ANALYSIS USING CONTINUOUS GLUCOSE MONITORING SYSTEM (CGMS)
    Popoviciu, Mihaela Simona
    Vesa, Cosmin
    Jurca, Aurora
    Jurca, Claudia
    Popa, Loredana
    Zaha, Dana
    Ceavoi, Gabriela
    Jurca, Alexandru
    FARMACIA, 2021, 69 (02) : 332 - 340
  • [26] Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement
    Rossi, Maria Chiara
    Lucisano, Giuseppe
    Ceriello, Antonio
    Mazzucchelli, Chiara
    Musacchio, Nicoletta
    Ozzello, Alessandro
    Nicolucci, Antonio
    Di Bartolo, Paolo
    ACTA DIABETOLOGICA, 2018, 55 (10) : 1059 - 1066
  • [27] Differences Between Glycated Hemoglobin and Glucose Management Indicator in Real-Time and Intermittent Scanning Continuous Glucose Monitoring in Adults With Type 1 Diabetes
    Yoo, Jee Hee
    Moon, Sun Joon
    Park, Cheol-Young
    Kim, Jae Hyeon
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [28] Patients’ and caregivers’ experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study
    J. Lawton
    M. Blackburn
    J. Allen
    F. Campbell
    D. Elleri
    L. Leelarathna
    D. Rankin
    M. Tauschmann
    H. Thabit
    R. Hovorka
    BMC Endocrine Disorders, 18
  • [29] Time in range-A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study
    Valenzano, Marina
    Bertolotti, Ivan Cibrario
    Valenzano, Adriano
    Grassi, Giorgio
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [30] Real-World Life Analysis of a Continuous Glucose Monitoring and Smart Insulin Pen System in Type 1 Diabetes: A Cohort Study
    Pantanetti, Paola
    Cangelosi, Giovanni
    Morales Palomares, Sara
    Ferrara, Gaetano
    Biondini, Federico
    Mancin, Stefano
    Caggianelli, Gabriele
    Parozzi, Mauro
    Sguanci, Marco
    Petrelli, Fabio
    DIABETOLOGY, 2025, 6 (01):